as reported April 1, 2002
Rigel Warns Physicians About Fatal Infections from Gavreto
Gavreto used to treat metastatic RET fusion-positive non-small cell lung cancer and RET fusion-positive thyroid cancer.
Read More
FDA Approves IV Form of Stelara Biosimilar Selardsi
This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.
FDA Approves First-in-Class Drug for Gastric Cancer
Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and gastroesophageal cancers.
Karen Lynch Steps Down as CEO of CVS Health
David Joyner has been appointed president and CEO of CVS Health effective immediately.
FDA Approves Imuldosa, the Fifth Stelara Biosimilar
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
FDA Approves Hympavzi for Hemophilia A and B
Hympavzi is the first anti-tissue factor pathway inhibitor approved in the United States for hemophilia.
